Influence of breast cancer subtype on pathological complete response
Keywords:
breast cancer, combined modality therapy, chemotherapyAbstract
Objective: To compare the rates of pathological complete response (pCR) after treatment with neoadjuvant chemotherapy, in the different subtypes of breast cancer in patients followed at the Mastology Service of Hospital do Servidor Público Estadual. Methods: Descriptive and retrospective study, in which medical records of 213 patients diagnosed with breast cancer and submitted to neoadjuvant chemotherapy were reviewed, from February 2011 through January 2018. Histological data collected were: hormone receptors, hyperexpression of HER-2, grade, histological type and clinical data: age of the patient at diagnosis, tumor size and clinical stage at diagnosis and after chemotherapy, and rate of pCR. Results: The mean age of patients at diagnosis was 53.97 years. Forty-six patients (21,6%) had pCR, 77 (36.1%) were grade 2 and 136 (63.9%) were grade 3. Regarding cancer subtype, 29 patients (13.6%) were reported to have pure HER2 subtype, 48 patients (22.5%) corresponded to Luminal A subtype, 51 (23.9%) to Luminal B, and 66 patients (31.0%) were characterized as Triple Negative, while only 17 patients (7.9%) had Luminal B HER. Conclusion: The subtypes Pure HER 2 and Luminal B had the highest pCR rates.
Downloads
References
Brasil. Ministério da Saúde. Tipos de câncer: câncer de mama [Internet]. Brasil: Instituto Nacional do Câncer [acessed on July 17, 2017]. Available at: http://www2.inca.gov.br/wps/wcm/connect/tiposdecancer/site/home/mama/cancer_mama
Bardia A, Baselga J. Neoadjuvant therapy as a platform for drug development and approval in breast cancer. Clin Cancer Res. 2013;19(23):6360-70. https://doi.org/10.1158/1078-0432.ccr-13-0916
Ueno NT, Buzdar AU, Singletary SE, Ames FC, McNeese MD, Holmes FA, et al. Combined-modality treatment of inflammatory breast carcinoma: Twenty years of experience at M.D. Anderson Cancer Center. Cancer Chemother Pharmacol. 1997;40(4):321-9. https://doi.org/10.1007/s002800050664
Pachnick JPA, Czeczko NG, Tuon F, Cavalcanti TS, Malafaia AB, Tuleski AM. Avaliação imunoistoquímica dos receptores de estrogênio e progesterona no câncer de mama, pré e pósquimioterapia neoadjuvante. Rev Col Bras Cir. 2012;39(2):86- 91. https://doi.org/10.1590/S0100-69912012000200002
Schwartz GF, Hortobagyi GN. Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26-28, 2003, Philadelphia, Pennsylvania. Cancer. 2004;100(12):2512-32. https://doi.org/10.1002/cncr.20298
Mamtani A, Barrio AV, King TA, Van Zee KJ, Plitas G, Pilewskie M, et al. How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study. Ann Surg Oncol. 2016;23(11):3467-74. https://dx.doi.org/10.1245%2Fs10434-016-5246-8
Spring L, Greenup R, Niemierko A, Schapira L, Haddad S, Jimenez R, et al. Pathologic complete response after neoadjuvant chemotherapy and long-term outcomes among young women with breast cancer. J Natl Compr Cancer Netw. 2017;15(10):1216-23. https://doi.org/10.6004/jnccn.2017.0158
Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, et al. Preoperative chemotherapy: Updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. J Clin Oncol. 2008;26(5):778-85. https://doi.org/10.1200/jco.2007.15.0235
Gralow JR, Burstein HJ, Wood W, Hortobagyi GN, Gianni L, Von Minckwitz G, et al. Preoperative therapy in invasive breast cancer: Pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol. 2008;26(5):814-9. https://doi.org/10.1200/jco.2007.15.3510
Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis. Lancet. 2014;384(9938):164-72. https://doi.org/10.1016/s0140-6736(13)62422-8
Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, et al. The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13(8):2329-34. https://doi.org/10.1158/1078-0432.ccr-06-1109
Precht LM, Lowe KA, Atwood M, Beatty JD. Neoadjuvant chemotherapy of breast cancer: Tumor markers as predictors of pathologic response, recurrence, and survival. Breast J. 2010;16(4):362-8. https://doi.org/10.1111/j.1524-4741.2010.00935.x
Monteiro H de AV, Goulart-Citrangulo SMT, Leite MS, Giacomin LC, Vianna-Jorge R. Influência de Variáveis Clinicopatológicas sobre a Eficácia da Quimioterapia Neoadjuvante do Câncer de Mama. Rev Bras Cancerol. 2013;59(3):369-77.
Santos TP, Paes MA, Ferreira ACS de M, Campos T. Avaliação epidemiológica das pacientes com câncer de mama tratadas com trastuzumabe no Hospital de Base de Brasília. Rev Bras Oncol Clínica. 2014;10(36):55-9.
Lopes LAF, Linhares, JJ, Ferraro O, Guedes R, Lopes C, Baracat FF. Valor prognóstico do grau histológico (GH), grau nuclear (GN) e índice mitótico (IM) para pacientes com carcinoma da mama estádios II e III com linfonodos axilares comprometidos. Rev Bras Cancerol. 2006;52(3):245-51.
Aquino RGF de, Pinheiro LGP, Cavalcante DIM, Vasques PHD, Oliveira AL de S, Silva CAB da. Carcinoma ductal invasor: comparação dos graus histológicos entre tumor primário e metástase axilar. Rev Bras Mastol. 2016;26(2):45-9.
Van Vaisberg V, Vilas Boas MDS, Stephan BDO, Matutino ARB, Lima JMDS, Mano MS. Câncer de mama: efeito prognóstico da resposta patológica completa após quimioterapia neoadjuvante. Rev Med. 2015;94(Supl.):31. https://doi.org/10.11606/issn.1679-9836.v94isupl.p31-31
Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJH, Mansel RE, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981- 22023 AMAROS): A randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303- 10. http://dx.doi.org/10.1016/S1470-2045(14)70460-7
BougheyJC, SumanVJ, MittendorfEA, AhrendtGM, WilkeLG, Taback B, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: The ACOSOG Z1071 (alliance) clinical trial. J Am Med Assoc. 2013;310(14):1455-61. https://dx.doi.org/10.1001%2Fjama.2013.278932
Silva EHL de S, Paloschi JRA, Caldeira JR de F, Joioso A. Estudo comparativo de resposta à quimioterapia neoadjuvante em dose total, entre câncer de mama e metástase axilar, conforme resultados de imunoistoquímica, no Serviço de Mastologia do Hospital Amaral Carvalho em Jaú, SP. Rev Bras Mastol. 2015;25(2):46-50. https://dx.doi.org/10.5327/Z201500020003RBM
Nitz U, Gluz O, Christgen M, Grischke EM, Augustin D, Kümmel S, et al. Final analysis of WSG-ADAPT HER2+/HR- trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant dual blockade with trastuzumab + pertuzumab ± weekly paclitaxel in HER2+/HR- early breast cancer (EBC). J 2016;34(15 Supl.):518. https://dx.doi.org/10.1200/JCO.2016.34.15_suppl.518ClinOncol.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Bruno de Carvalho Mancinelli, Marcelo Antonini, Flávia Vasconcelos da Silva, Odair Ferraro, Reginaldo Guedes Coelho Lopes
This work is licensed under a Creative Commons Attribution 4.0 International License.
